| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2021: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2020: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2019: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2018: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Outline of Final Research Achievements |
Herpesviruses, especially alphaherpesviruses, are latently infected after acute infection in natural hosts, but are known to cause fatal encephalitis when they infect non-natural hosts. In this study, we found that acylation of UL11, the smallest protein encoded by EHV-1, is essential for viral replication, and confirmed that viruses with non-acylating mutations in UL11 (EHV-1 UL11 G2A/C7A/C9A) are growth-restricted virus.EHV-1 UL11 G2A/C7A/C9A-inoculated mice were able to prevent infection with neuropathogenic EHV-1. Based on these results, we were able to construct a growth-restricted vaccine due to acylation deficiency.
|
